Gene Security Network strings together $6M for in-vitro tech
Gene Security Network, provider of a test used to screen chromosomes in in-vitro fertilization processes, has brought in $6 million in second-round funding to grow its sales and marketing operations. The investment, paired with grants received from the National Institutes of Health, will give the Redwood City, Calif. company a two-year runway, it says.
The test, already being sold, detects chromosomal abnormalities that might lead to Down Syndrome and other conditions. It’s currently being offered at select in-vitro fertilization clinics across the country.
Claremont Creek Ventures led the round, which also included Sequoia Capital and Alafi Capital. Gene Security Network has raised $10 million to date.
Next Story: Achaogen takes in $5.6M to fight bacterial infections
Previous Story: Twitter moves beyond blaming top users for its issues
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.